TFS Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

TFS Capital’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-65,553	Closed	-$614K	–	427
2017 Q2	$614K	Buy	+65,553	New	+$481K	0.24%	137
2017 Q1	–	Sell	-51,561	Closed	-$382K	–	912
2016 Q4	$382K	Buy	51,561 +34,263	+198%	+$247K	0.1%	351
2016 Q3	$104K	Buy	17,298 +6,912	+67%	+$32.7K	0.02%	640
2016 Q2	$47K	Sell	10,386 -46,323	-82%	-$174K	0.01%	920
2016 Q1	$141K	Buy	+56,709	New	+$207K	0.02%	833
2015 Q2	–	Sell	-12,343	Closed	-$93K	–	1139
2015 Q1	$93K	Buy	+12,343	New	+$96.4K	0.01%	888
2014 Q3	–	Sell	-24,817	Closed	-$145K	–	1274
2014 Q2	$145K	Buy	+24,817	New	+$139K	0.01%	1008

Other funds holding CCXI

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

TFS Capital's CCXI Position: Q3 2017 in Review

TFS Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2017, closing a stake of 65,553 shares — an estimated $614K sold.

TFS Capital first reported a position in CCXI in Q2 2014 and held it in 7 quarters. The position peaked at $614K in Q2 2017. 86 funds tracked by Wall St. Rank hold CCXI as of Q3 2017.

TFS Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2017 after selling out during the quarter.
TFS Capital sold 65,553 ChemoCentryx, Inc. shares in Q3 2017, an estimated $614K.
TFS Capital first reported a position in ChemoCentryx, Inc. in Q2 2014 and held it in 7 quarters.
TFS Capital's ChemoCentryx, Inc. position peaked at $614K in Q2 2017.
86 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2017.

Based on TFS Capital's 13F filing for Q3 2017.